AdvisorShares Psychedelics ETF Rating $20.33 +0.04 (+0.20%) As of 11:41 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatings AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.64Holdings in PSIL have an aggregate rating of Moderate Buy based on 239 analyst ratings issued in the past year covering 20 companies (81.2% of the portfolio).PSIL Aggregate Price Target$20.29High Prediction$20.29Average Prediction$20.29Low Prediction$20.29Holdings in PSIL have an aggregate price target of $20.29 and a range of $20.29 to $20.29 covering 20 companies (81.2% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell2 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 20 PSIL Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings11.83%DFTXDefinium Therapeutics$34.53+0.4%Moderate Buy$66.00 91.1%213.3099 of 5 stars11.23%CMPSCompass Pathways$11.27+1.2%Moderate Buy$23.36 107.2%172.6276 of 5 starsPositive News4.78%RLMDRelmada Therapeutics$3.29-2.2%Moderate Buy$12.00 265.3%82.7996 of 5 stars4.70%NBIXNeurocrine Biosciences$136.14+0.7%Moderate Buy$201.14 47.7%244.8341 of 5 starsNews CoverageAnalyst Forecast4.68%LLYEli Lilly and Company$1,213.18+4.0%Moderate Buy$1,313.43 8.3%294.851 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision4.60%ABBVAbbVie$283.67+3.4%Moderate Buy$277.18 -2.3%304.0001 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision4.47%NRXPNRx Pharmaceuticals$2.62-3.1%Hold$34.50 1,219.3%71.9027 of 5 stars4.41%GHRSGH Research$18.63-1.2%Moderate Buy$45.00 141.5%123.3667 of 5 stars4.35%JNJJohnson & Johnson$252.34+1.5%Moderate Buy$273.61 8.4%254.4879 of 5 starsTrending NewsEarnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision4.02%ANROAlto Neuroscience$22.23+0.6%Moderate Buy$37.25 67.6%111.7338 of 5 starsNews Coverage4.00%STIMNeuronetics$1.91-4.3%Moderate Buy$4.67 145.0%53.5562 of 5 starsPositive News3.56%ALKSAlkermes$40.02+0.7%Moderate Buy$54.47 36.1%193.1689 of 5 stars3.47%SPTXSeaport Therapeutics$16.62+3.4%Moderate Buy$37.25 124.1%132.7951 of 5 starsAnalyst Forecast3.23%SUPNSupernus Pharmaceuticals$42.76+1.8%Hold$62.40 45.9%63.4129 of 5 starsNews Coverage2.76%PBMPsyence Biomedical$4.41-3.0%Strong Sell11.5873 of 5 starsPositive NewsShort Interest Decrease2.14%NEUPNeuphoria Therapeutics$3.35-1.3%Reduce$7.00 109.2%32.8398 of 5 stars1.10%KTTAPasithea Therapeutics$0.42-1.4%Hold$3.00 617.7%33.6872 of 5 starsPositive NewsShort Interest DecreaseGap Up1.07%IXHLIncannex Healthcare$2.87-1.5%Reduce$18.00 528.3%32.9089 of 5 starsShort Interest Decrease0.49%IGCIGC Pharma$0.26-1.5%Moderate Buy$5.50 2,007.3%22.63 of 5 starsNews Coverage0.30%SILOSilo Pharma$1.23+0.8%Strong Sell10.6577 of 5 starsPositive News This page (NYSEARCA:PSIL) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
